Danaher Corporation $DHR Position Boosted by Sivik Global Healthcare LLC

Key Points

• Sivik Global Healthcare LLC increased its stake in Danaher Corporation by 14.3%, owning 40,000 shares valued at approximately $7.9 million.
• Danaher reported earnings per share of $1.80 for the last quarter, surpassing estimates, with a quarterly revenue of $5.94 billion.
• The company recently announced a quarterly dividend of $0.32 per share, with an expected annualized dividend yield of 0.6%.

Sivik Global Healthcare LLC raised its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 14.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,000 shares of the conglomerate's stock after acquiring an additional 5,000 shares during the quarter. Danaher makes up 2.1% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 8th largest holding. Sivik Global Healthcare LLC's holdings in Danaher were worth $7,902,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nuveen LLC bought a new stake in shares of Danaher in the 1st quarter valued at approximately $833,941,000. Invesco Ltd. grew its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. grew its stake in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock valued at $295,550,000 after buying an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP grew its stake in shares of Danaher by 33.2% in the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock valued at $651,515,000 after buying an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC grew its stake in shares of Danaher by 23.3% in the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock valued at $784,745,000 after buying an additional 722,636 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on DHR. Guggenheim reissued a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Robert W. Baird boosted their price target on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a report on Friday, July 11th. Finally, Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and a consensus price target of $244.60.

Danaher Stock Performance

DHR opened at $202.53 on Friday. The stock has a market cap of $145.02 billion, a PE ratio of 43.09, a P/E/G ratio of 2.88 and a beta of 0.77. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.41. The stock's 50 day simple moving average is $200.66 and its 200-day simple moving average is $197.16.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's payout ratio is currently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.